Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (GB:0I3Q)
LSE:0I3Q
Holding GB:0I3Q?
Track your performance easily
0I3Q Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.88 - $39.52
Previous Close$35
Volume373.00
Average Volume (3M)528.00
Market Cap
$3.67B
Enterprise Value$3.20B
Total Cash (Recent Filing)$473.16M
Total Debt (Recent Filing)$5.67M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Oct 30, 2024EPS Estimate
$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding104,492,469
10 Day Avg. Volume274
30 Day Avg. Volume528
Standard Deviation0.14
R-Squared0.03
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.16
Price to Sales (P/S)6.45
Price to Cash Flow (P/CF)22.30
P/FCF Ratio22.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.63
Enterprise Value/Gross Profit6.73
Enterprise Value/Ebitda21.98
Forecast
1Y Price Target
$53.67Price Target Upside53.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Corcept Therapeutics News
PremiumCompany Announcements
Corcept Therapeutics Releases Q2 2024 Financial Results
PremiumPre-Earnings
Is CORT a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial PerformanceKorlym sales revenue was $163.8M for the quarter, and beat both our estimate and the Street consensus.
Market PotentialPhysicians are increasingly aware that hypercortisolism is much more prevalent than was previously assumed and therefore are screening more patients for the disorder, which ultimately leads to an increase in new scripts of Korlym as more patients are identified.
Product ExpansionThe company is also expanding into other disease areas, including oncology and metabolic disorders, with an ongoing Phase III trial in platinum-resistant ovarian cancer and earlier phase trials in prostate cancer, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH).
Bears Say
Clinical TrialsThere remains clinical risk on the overall outcome of the GRACE trial, as well as the regulatory and commercial future associated with it.
LawsuitTEVA filed a lawsuit against CORT claiming Korlym's orphan pricing is egregious and that some of CORT's patents are invalid.
Sales Practices InvestigationTEVA's accusations of doctor kickbacks is essentially a re-hash of the ongoing NJ USAO's investigations into CORT's sales practices.
---
0I3Q FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest share price was $20.88 and its highest was $39.52 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is Oct 30, 2024 which is in 59 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Jul 29, 2024. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.09.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is $0.27.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 104,492,470 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.32 in its last earnings report, beating expectations of $0.23. Following the earnings report the stock price went down -3.624%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 11M.
---
Corcept Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.67 (53.34% Upside)
$53.67 (53.34% Upside)
Blogger Sentiment
Bullish
GB:0I3Q Sentiment 100%
Sector Average 68%
Sector Average 68%
Insider Transactions
Sold Shares
Worth $110.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.39%
12-Months-Change
Fundamentals
Return on Equity
24.55%
Trailing 12-Months
Asset Growth
36.20%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
0I3Q Earnings Call
Q2 2024
0:00 / 0:00
---
0I3Q Stock 12 Month Forecast
Average Price Target
$53.67
▲(53.34% Upside)
Technical Analysis
Corcept Therapeutics
―
Aclaris Therapeutics
―
Arrowhead Pharmaceuticals
―
BioCryst
―
Kala Pharmaceuticals
―
Best Analysts Covering 0I3Q
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+17.51%
reiterated a buy rating 18 days ago
Copying Edward Nash's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +17.51% per trade.
---